Cutaneous T Cell Lymphoma: Clinical Trials

12 trials for Cutaneous T Cell Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 4 recruiting, 1 active not recruiting, 1 unknown. 12 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 212Completed 6, Recruiting 4, Active not recruiting 1, Unknown 1
Phase 12Completed 2

Follow Cutaneous T Cell Lymphoma: new trials by email Literature Review of Cutaneous T Cell Lymphoma trials Research Report on Cutaneous T Cell Lymphoma

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Ruxolitinib, Positron emission tomography-computed tomography, Bone Marrow Biopsy - T-cell Lymphoma, Graft Versus Host Disease
Phase 2RecruitingOhio State University Comprehensive Cancer Center442026-02-122026-10-27
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
JAK1 Inhibitor - Lymphoma, T-Cell, NK-LGL Leukemia
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China482024-12-252025-11-18
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
Pembrolizumab, Mogamulizumab - Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome
Phase 2RecruitingUniversity of Michigan Rogel Cancer Center232023-12-062026-05-05
Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light
Hypericin, Visible Light - Cutaneous T Cell Lymphoma, Mycosis Fungoides
Phase 2CompletedEllen Kim, MD102023-08-212026-02-09
Photopheresis in Early-stage Mycosis Fungoides
UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis, THERAKOS® CELLEX photopheresis system - Cutaneous T Cell Lymphoma, Mycosis Fungoides
Phase 2RecruitingColumbia University742021-05-082026-04-27
A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)
Pembrolizumab, Radiotherapy - Cutaneous T Cell Lymphoma, Mycosis Fungoides/Sezary Syndrome
Phase 2Active not recruitingUniversity College, London462019-01-152024-12-09
A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)
Placebo, CD11301 0.03%, CD11301 0.06% - Cutaneous T Cell Lymphoma
Phase 2CompletedGalderma R&D862017-12-192021-04-08
Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)
Dimethyl fumarate - Cutaneous T Cell Lymphoma
Phase 2CompletedUniversitätsmedizin Mannheim252015-09-012023-03-31
Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)
Topical resiquimod 0.06%, topical resiquimod 0.03% - Cutaneous T Cell Lymphoma
Phase 1 / Phase 2CompletedAbramson Cancer Center at Penn Medicine132012-02-012019-08-13
RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas
RAD001 (Everolimus) - Peripheral T Cell Lymphoma Unspecified, Anaplastic Large Cell Lymphoma, ALK-negative
Phase 1 / Phase 2CompletedSamsung Medical Center462010-07-012015-03-03
Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma
Lenalidomide - Cutaneous T Cell Lymphoma
Phase 2UnknownFlorida Academic Dermatology Centers102010-05-012010-05-28
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Romidepsin - Cutaneous T Cell Lymphoma, Peripheral T Cell Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)1312001-03-082017-05-16

Narrower conditions

Lymphoma, T-Cell, Cutaneous (12)  ·  Mycosis Fungoides (5)  ·  Lymphoma, T-Cell (3)  ·  Lymphoma (2)  ·  Lymphoma, T-Cell, Peripheral (2)  ·  Sezary Syndrome (2)  ·  Graft vs Host Disease (1)  ·  Immunoblastic Lymphadenopathy (1)  ·  Leukemia (1)  ·  Leukemia, Large Granular Lymphocytic (1)  ·  Leukemia, Prolymphocytic, T-Cell (1)  ·  Lymphoma, Large-Cell, Anaplastic (1)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Recurrence (1)

Broader conditions

Hemic and Lymphatic Diseases (12)  ·  Immune System Diseases (12)  ·  Immunoproliferative Disorders (12)  ·  Lymphatic Diseases (12)  ·  Lymphoma, Non-Hodgkin (12)  ·  Lymphoproliferative Disorders (12)  ·  Neoplasms (12)  ·  Neoplasms by Histologic Type (12)  ·  Lymphoma (10)  ·  Lymphoma, T-Cell (9)  ·  Hematologic Diseases (2)  ·  Leukemia, Lymphoid (2)  ·  Leukemia, T-Cell (2)  ·  Disease Attributes (1)  ·  Leukemia (1)

Interventions

pembrolizumab (2)  ·  Biopsy (1)  ·  Cyclophosphamide (1)  ·  Dimethyl Fumarate (1)  ·  Doxorubicin (1)  ·  Everolimus (1)  ·  Lenalidomide (1)  ·  Light (1)  ·  Methoxsalen (1)  ·  Prednisolone (1)  ·  Radiotherapy (1)  ·  TNTCFP protein (1)  ·  Vincristine (1)  ·  hypericin (1)  ·  mogamulizumab (1)

Sponsors

Abramson Cancer Center at Penn Medicine (1)  ·  Columbia University (1)  ·  Ellen Kim, MD (1)  ·  Florida Academic Dermatology Centers (1)  ·  Galderma R&D (1)  ·  Institute of Hematology & Blood Diseases Hospital, China (1)  ·  National Cancer Institute (NCI) (1)  ·  Ohio State University Comprehensive Cancer Center (1)  ·  Samsung Medical Center (1)  ·  University College, London (1)  ·  University of Michigan Rogel Cancer Center (1)  ·  Universitätsmedizin Mannheim (1)

Countries

United States (8)  ·  Germany (2)  ·  Australia (1)  ·  China (1)  ·  France (1)  ·  South Korea (1)  ·  United Kingdom (1)

Top investigators

Alain H Rook, M.D. (1)  ·  James Gulley, M.D. (1)  ·  Jonathan Brammer, MD (1)  ·  Larisa Geskin, MD (1)  ·  Ryan Wilcox (1)  ·  Tim Illidge (1)  ·  Won Seog Kim, MD, PhD (1)

Results publications

PMID 19826128, PMID 21355097, PMID 25891346, PMID 26228486, PMID 28264616, PMID 32632956, PMID 33072126, PMID 37217183, PMID 39821757

NIH funding

2017 (1)